Polycyclic compounds that are aromatic or partially aromatic, and are substituted with one or more alkyl groups having an amino group and a carboxylic acid group, and includes carbon quantum dots (CQDs) that contain these compounds. The compounds and CQDs have a selective affinity for cells that express LAT1 and for tumor cells, and can internalize within such cells. The compounds and CQDs are useful for imaging of such cells and for delivering cargo compounds to and into cells that express LAT1 and tumor cells. Methods for making and using these compounds and CQDs for bioimaging and targeting certain tissues, including tumors, are disclosed.

The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.

Poly(amidoamine) [PAMAM] dendrimers for use as PSMA-targeted contrast agents for optical and photoacoustic imaging (PA) and theranostic agents for treating prostate cancer are disclosed.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

A system comprising: one or more field generating coils configured to generate a magnetic field; a sensor comprising a shell that contains a ferrofluid, the sensor configured to be introduced in proximity to the magnetic field, wherein the ferrofluid causes distortion of the magnetic field when the ferrofluid is in proximity to the magnetic field; and one or more field measuring coils configured to: measure a characteristic of the magnetic field when the ferrofluid is in proximity to the magnetic field; and provide, to a computing device, a signal representative of the measured characteristic of the magnetic field, wherein the computing device is configured to determine one or both of a position and an orientation of the sensor based on the measured characteristic of the magnetic field.

A predetermined bone site in a patient selected for restoration is exposed, contacted with an aqueous, methylene blue containing phosphoric acid solution for a time period of at least 3 minutes but no more than about 15 minutes, and thereafter cleansed ultrasonically to remove any bacteria that may be present. Preferred phosphoric acid concentration in the aqueous solution is about 37 percent by weight.

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.